Ref: MHL/Sec&Legal/2020-21/171 Date: February 10, 2021
To, Head, Listing Compliance Department Head, Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block, Dalal Street, Mumbai - 400 001. Bandra -Kurla Complex, Bandra (East), Mumbai- 400051. Scrip Code: 542650 Scrip Symbol: METROPOLIS
Sub: Outcome of Board Meeting held on Wednesday, February 10, 2021
Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR’)
Dear Sir/Madam,
This is to inform you that the Board of Directors of the Company at their meeting held today have inter- alia: i. Approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and nine months ended December 31, 2020 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and nine months ended December 31, 2020.
The copy of the Unaudited Standalone & Consolidated Financial Statements of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter and nine months ended December 31, 2020 is enclosed as Annexure – 1. ii. Approved the re-appointment of Ms. Ameera Sushil Shah as the Managing Director, for a period of five years with effect from March 18, 2021, as per the recommendation of the Nomination and Remuneration Committee, subject to approval of members of the Company at the ensuing Annual General Meeting.
The necessary details as required pursuant to Regulation 30 of SEBI LODR read with SEBI Circular CIR/CFD/CMD/4/2015 are enclosed as Annexure – 2. iii. Approved and declared payment of Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per equity share on the Face Value Rs. 2 (Rupees Two only) each for the financial year 2020- 2021.The interim dividend will be paid to the members whose names appear in the Register of Members / Register of beneficiaries as on the ‘Record Date’ i.e. February 19, 2021.The Interim Dividend will be paid to the shareholders within 30 days of declaration.
BLOOD TESTS • DIAGNOSTICS • WELLNESS
Metropolis Healthcare Limited Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030. CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [email protected] Website: www.metropolisindia.com Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.
iv. Approved the change in constitution of the Nomination and Remuneration Committee of the Company with effect from February 10, 2021. The details of change in the Committee constitution is enclosed as Annexure – 3.
The meeting commenced at 2:00 p.m. and concluded at 4:10 p.m.
Thanking you, Yours faithfully
For Metropolis Healthcare Limited
Poonam Tanwani Company Secretary & Compliance Officer Membership No. A19182 Encl. a/a
BLOOD TESTS • DIAGNOSTICS • WELLNESS
Metropolis Healthcare Limited Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030. CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [email protected] Website: www.metropolisindia.com Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070. B S R & Co. LLP Chartered Accountants
14th Floor, Central B Wing and North C Wing, Telephone: +91 22 6257 1000 Nesco IT Park 4, Nesco Center, Fax: +91 22 6257 1010 Western Express Highway, Goregaon (East), Mumbai - 400 063
Limited review report on unaudited quarterly and year-to-date standalone financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 To the Board of Directors of Metropolis Healthcare Limited
1. We have reviewed the accompanying Statement of unaudited standalone financial results of Metropolis Healthcare Limited (‘the Company’) for the quarter ended 31 December 2020 and year to date results for the period from 1April 2020 to 31 December 2020 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
For B S R & Co. LLP Chartered Accountants Firm’s Registration No: 101248W/W-100022
Digitally signed by TARUN K TARUN K KINGER Date: 2021.02.10 KINGER 14:37:53 +05'30' Tarun Kinger Partner Mumbai Membership No: 105003 10 February 2021 ICAI UDIN: 21105003AAAAAQ9052
Registered Office:
B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 Center, Western Express Highway, Goregaon (East), Mumbai - 400063 0HWURSROLV+HDOWKFDUH/LPLWHG 5HJLVWHUHGDQG&RUSRUDWH2IILFH '8G\RJ%KDYDQ+LQG&\FOH0DUJ:RUOL0XPEDL &,1 /0+3/& 7HO1R (PDLO VXSSRUW#PHWURSROLVLQGLDFRP :HEVLWH ZZZPHWURSROLVLQGLDFRP *OREDO5HIHUHQFH/DE WK)ORRU&RPPHUFLDO%OGJ$.RKLQRRU0DOO9LG\DYLKDU :HVW 0XPEDL
6WDWHPHQWRI6WDQGDORQH)LQDQFLDO5HVXOWVIRUWKHTXDUWHUDQGQLQHPRQWKHQGHG'HFHPEHU
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±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±ZLVHLQIRUPDWLRQLVQRWDSSOLFDEOHDVSDWKRORJ\VHUYLFHVLVWKH&RPSDQ\RQO\EXVLQHVVVHJPHQW 7KH 1RPLQDWLRQ DQG 5HPXQHUDWLRQ &RPPLWWHH RI WKH %RDUG RI 'LUHFWRUV RI WKH &RPSDQ\ KDYH RQ 1RYHPEHU DSSURYHG JUDQW RI 5HVWULFWHG 6WRFN 8QLWV 568 SXUVXDQW WR WKH 0HWURSROLV ± 5HVWULFWLYH 6WRFN 8QLW 3ODQ ± WR HOLJLEOH HPSOR\HHV RI WKH &RPSDQ\ WKLV LV LQ DGGLWLRQ WR WKH 568 V DSSURYHG XQGHU 5HVWULFWLYH 6WRFN 8QLW 3ODQ ±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µ&RGH¶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o. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing, Telephone: +91 22 6257 1000 Nesco IT Park 4, Nesco Center, Fax: +91 22 6257 1010 Western Express Highway, Goregaon (East), Mumbai - 400 063 Limited review report on unaudited quarterly and year-to-date consolidated financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 To the Board of Directors of Metropolis Healthcare Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Metropolis Healthcare Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), and its share of the net loss after tax and total comprehensive loss of its joint venture for the quarter ended 31 December 2020 and year to date results for the period 1 April 2020 to 31 December 2020 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’). 2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable. Registered Office: B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 Center, Western Express Highway, Goregaon (East), Mumbai - 400063 B S R & Co. LLP Limited review report on unaudited quarterly and year-to-date consolidated financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued) 4. The Statement includes the results of the following entities: Sr No Name of Entity Relationship 1 Sudharma Metropolis Health Services Private Limited Subsidiary 2 Bokil Golwilkar Metropolis Healthcare Private Limited Subsidiary 3 Raj Metropolis Healthcare Private Limited Subsidiary 4 Desai Metropolis Health Services Private Limited Subsidiary 5 R.V. Metropolis Diagnostics & Healthcare Centre Private Limited Subsidiary 6 Micron Metropolis Healthcare Private Limited Subsidiary 7 Dr. Patel Metropolis Healthcare Private Limited Subsidiary 8 Lab One Metropolis Healthcare Services Private Limited Subsidiary 9 Amins Pathology Laboratory Private Limited Subsidiary 10 Ekopath Metropolis Lab Services Private Limited Subsidiary 11 Metropolis Healthcare Lanka Private Limited Subsidiary 12 Metropolis Healthcare (Mauritius) Limited Subsidiary 13 Metropolis Star Lab Kenya Limited Subsidiary 14 Metropolis Healthcare Ghana Limited Subsidiary 15 Metropolis Bramser Lab Services (Mtius) Limited Subsidiary 16 Metropolis Healthcare (Tanzania) Limited Subsidiary 17 Metropolis Histoxpert Digital Services Private Limited Joint Venture 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. B S R & Co. LLP Limited review report on unaudited quarterly and year-to-date consolidated financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued) 6. The Statement includes interim financial information of six (6) subsidiaries, which have not been reviewed, whose interim financial information reflects total revenue of Rs 997.15 lakhs and Rs 2,644.89 lakhs, total net profit after tax of Rs 122.72 lakhs and Rs 5.98 lakhs and total comprehensive income of Rs 103.73 lakhs and Rs 172.56 lakhs for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020, respectively, as considered in the Statement. These financial information have been furnished to us by the management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, are based solely on such management certified financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter. For B S R & Co. LLP Chartered Accountants Firm’s Registration No: 101248W/W-100022 Digitally signed by TARUN K TARUN K KINGER Date: 2021.02.10 KINGER 14:38:51 +05'30' Tarun Kinger Partner Mumbai Membership No: 105003 10 February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± 2WKHUFRPSUHKHQVLYHLQFRPH ,WHPVWKDWZLOOQRWEHUHFODVVLILHGVXEVHTXHQWO\WRSURILWDQGORVV QHWRIWD[ ,WHPVWKDWZLOOEHVXEVHTXHQWO\UHFODVVLILHGWRSURILWDQGORVV QHWRIWD[ 2WKHUFRPSUHKHQVLYHLQFRPH ORVV IRUWKHSHULRG\HDU QHWRIWD[ ϭϭ 7RWDOFRPSUHKHQVLYHLQFRPH ϭϮ 3URILW ORVV DWWULEXWDEOHWR 2ZQHUVRIWKH&RPSDQ\ 1RQFRQWUROOLQJLQWHUHVW ϭϯ 2WKHUFRPSUHKHQVLYHLQFRPH ORVV DWWULEXWDEOHWR 2ZQHUVRIWKH&RPSDQ\ 1RQFRQWUROOLQJLQWHUHVW ϭϰ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¶RUWKHµ3DUHQW DQGLWVVXEVLGLDULHV UHIHUUHGWRFROOHFWLYHO\DVWKHµ*URXS¶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±ZLVHLQIRUPDWLRQLVQRWDSSOLFDEOHDVSDWKRORJ\VHUYLFHVLVWKH*URXS¶VRQO\EXVLQHVVVHJPHQW 7KH 1RPLQDWLRQ DQG 5HPXQHUDWLRQ &RPPLWWHH RI WKH %RDUG RI 'LUHFWRUV RI WKH &RPSDQ\ KDYH RQ 1RYHPEHU DSSURYHG JUDQW RI 5HVWULFWHG 6WRFN 8QLWV 568 SXUVXDQWWRWKH0HWURSROLV±5HVWULFWLYH6WRFN8QLW3ODQ±WRHOLJLEOHHPSOR\HHVRIWKH&RPSDQ\WKLVLVLQDGGLWLRQWRWKH568 VDSSURYHGXQGHU5HVWULFWLYH6WRFN8QLW3ODQ±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µ&RGH¶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nnexure – 2 : Details of Director being re-appointed Name of Director Ms. Ameera Sushil Shah DIN 00208095 Reason for change viz. Re-appointment of Ms. Ameera Sushil Shah as the Managing Director of the appointment, resignation, Company for a further period of five years with effect from March 18, 2021, removal, death or otherwise subject to the approval of the members of the Company at the ensuing General Meeting. Date of appointment / cessation With effect from March 18, 2021, for a period of five years, subject to the (as applicable) and terms of approval of the members of the Company. appointment Brief Profile Ms. Ameera Sushil Shah, is the Promoter & Managing Director of the Company. She has been associated with the Company as a Director on the Board, since 2008. She holds degree in Finance from The University of Texas at Austin and the prestigious Owner of President Management Program at Harvard Business School. For the last 20 years, she has focused on delivering sustained growth, built and led corporate functions of the Company, including finance, strategy, business process optimization, innovation and investor relations etc. Under her leadership, Metropolis raised the bar of diagnostic accuracy, technological equipment, customer experience, and research-driven, empathetic service. She was named amongst ‘Asia’s Most Powerful Women in Business’ by Forbes Asia and ‘Fifty Most Powerful Women in Business’ by Fortune India. She is recognized as a global thought leader in the healthcare industry. She has also played an instrumental role in changing the pathology industry landscape in the country; from being a doctor led practice to a professional corporate group in an extremely unregulated, competitive and fragmented market. Disclosure of relationship Ms. Ameera Sushil Shah is the daughter of Dr. Sushil Kanubhai Shah, the between Directors Chairman and Executive Director of the Company. Information as required pursuant Ms. Ameera Sushil Shah is not debarred from holding the office of the director to BSE Circular with ref. no. LIST / by virtue of any SEBI order or any other such authority. COMP/14/2018-2019 and the National Stock Exchange of India Ltd. with ref. no. NSE/CML/2018/24, dated 20th June, 2018 BLOOD TESTS • DIAGNOSTICS • WELLNESS Metropolis Healthcare Limited Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030. CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [email protected] Website: www.metropolisindia.com Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070. Annexure – 3 : Revised constitution of the Nomination and Remuneration Committee Present Composition up to February 10, 2021 Revised Composition with effect from February 10, 2021 1. Mr. Vivek Gambhir – Chairman 1. Ms. Anita Ramachandran – Chairperson 2. Ms. Anita Ramachandran – Member 2. Mr. Vivek Gambhir - Member 3. Mr. Sanjay Bhatnagar – Member 3. Mr. Sanjay Bhatnagar - Member BLOOD TESTS • DIAGNOSTICS • WELLNESS Metropolis Healthcare Limited Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030. CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [email protected] Website: www.metropolisindia.com Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.